Vaccine recommended to help protect persons over 10 years old in the United States (US) against disease-causing serogroups of Neisseria meningitidis (A, B, C, W, and Y) Broad serogroup coverage in one ...

Any infection caused by the Neisseria meningitidis (N. meningitidis) bacteria is called meningococcal disease. Meningococcal disease is very serious. It can lead to limb amputations, hearing loss, ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug Administration ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease Control ...

Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...

GSK has received the Food and Drug Administration’s permission for Penmenvy (meningococcal groups A, B, C, W and Y vaccine) for use in individuals aged 10 through 25 years. The vaccine targets five ...

Please provide your email address to receive an email when new articles are posted on . Penmenvy protects against meningococcal serotypes A, B, C, W and Y. CDC vaccine advisors are set to discuss ...

Broad serogroup coverage in one vaccine reduces injections to help improve vaccination rates and help protect more US adolescents and young adults Tony Wood, Chief Scientific Officer, GSK, said: "We ...

GSK plc announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend use of Penmenvy (Meningococcal Groups A, B, ...